The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
O. L. Chinot
Consultant or Advisory Role - Roche
Research Funding - Roche
W. Wick
Consultant or Advisory Role - Roche/Genentech
F. Saran
Consultant or Advisory Role - Roche
W. P. Mason
Consultant or Advisory Role - Roche
R. Henriksson
Consultant or Advisory Role - Roche
Honoraria - Roche
R. Nishikawa
Honoraria - Merck
A. H. Zeaiter
Employment or Leadership Position - Roche
N. Moore
Employment or Leadership Position - Roche
Stock Ownership - Roche
A. Das
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche
T. F. Cloughesy
Consultant or Advisory Role - Roche
Honoraria - Roche/Genentech
Research Funding - Genentech
Expert Testimony - Genentech